By Connor Hart
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.
The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial, which showed a 36% reduction in the risk of disease progression or death versus chemotherapy.
The approval extends to adult patients with unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, the company said.
"This new approval brings this important medicine to an earlier treatment setting and a broader patient population with HER2-expressing metastatic breast cancer," said Dave Fredrickson, executive vice president of AstraZeneca's oncology hematology business unit.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 27, 2025 18:59 ET (23:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.